ENTITY
Abbott India

Abbott India (BOOT IN)

64
Analysis
Health Care • India
Abbott India Limited manufactures a wide range of pharmaceutical and medical products, agrochemicals, and animal health products. The Company's medical and pharmaceutical products include insulin injections, anti-dysentery drugs, vitamin preparations, penicillin preparations, sulfonamide tablets, and a variety of household remedies.
more
•08 Oct 2022 02:20•Broker

Axis Research Scorecard Report - Sep 22

Axis Top Picks basket reported a resilient performance with an astounding return of 143% since its inception, notably beating an 84% return...

Logo
374 Views
Share
bullish•Abbott India
•12 Aug 2022 21:37•Broker

Abbott India Ltd - Key Therapies Report Robust Sales Improvement

AIL reported revenue growth of 7.1% YoY in Q1FY23 (vs. our expectations of 8% YoY), outpacing the IPM* growth of 2.0% (IPM: Indian Pharma Industry,...

Logo
332 Views
Share
•12 Apr 2022 17:23•Broker

Pharma Q4FY22 Preview: Cost Pressure and Pricing Erosion Compress Margins

We expect companies under our Pharma coverage to report high singledigit growth (6.2% YoY), primarily driven by Injectable and Generic segment.

Logo
353 Views
Share
bullish•Abbott India
•11 Jan 2022 17:07•Broker

Pick of the Week: Abbott India Ltd

Revenue growth of Abbott India Ltd (AIL) for FY21 has outpaced the Indian Pharma Market (IPM) growth by 100 bps majorily contributed by addition of...

Logo
286 Views
Share
bullish•Abbott India
•16 Nov 2021 17:47•Broker

Abbott India: Key Therapies Report Robust Sales Improvement

AIL reported revenue growth of 15.9% in Q2FY22, outpacing the IPM (Indian Pharma Industry, Source: AIOCD) growth of 14.6%.

Logo
248 Views
Share
x